FDA Panel Addresses Future Uterine Fibroid Treatment Studies
This article was originally published in The Gray Sheet
Executive SummaryImprovements in a patient's quality of life and bleeding should be sufficient measures to gauge the safety and effectiveness of new treatments for symptomatic uterine fibroids, an FDA advisory panel recommends
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.